AbbVie Banks On “Pipeline In A Molecule” Strategy For Imbruvica
AbbVie CEO Richard Gonzalez defended the roughly $21 billion purchase price it offered to pay for Pharmacyclics, citing bullish long-term sales projections for Imbruvica driven by indication expansion.
You may also be interested in...
With continued strong growth for Humira, AbbVie doubles down on confidence to protect the franchise with IP strategy. Imbruvica and Viekira Pak show growth, although the latter is flourishing only ex-US.
Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.